Indiana University School of Medicine
Indianapolis, IN 46202
Bio
Dr. Tao Lu has an extensive background in signaling transduction, molecular and cellular biology, biochemistry, genetics, and pharmacology with specific expertise in NF-kB signaling, post-translational modification, cancer epigenetics, and drug discovery. Born in a physician and medical professor’s family, Dr. Lu was fascinated by medical science from a very young age. She studied signaling transduction in cell death during her graduate study with Dr. Ronald L. Mellgren. Her postdoctoral training was with the world renowned cancer biologist and geneticist Dr. George R. Stark, who discovered Interferon/JAK/Stat pathway. Dr. Lu was an Assistant Professor at Lerner College of Medicine at Case Western Reserve University (CWRU) before she relocated to Indianapolis. She now is an Associate Professor with tenure at Department of Pharmacology & Toxicology, and an adjunct Associate Professor at Department of Biochemistry & Molecular Biology, as well as Department of Medical and Molecular Genetics. Dr. Lu is also a full member of the Experimental and Developmental Therapeutics (EDT) Program at IU Simon Cancer Center (IUSCC) - a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center.
|
|
Positions |
|
2019-present
2019-present |
Associate Professor (with tenure), Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN Adjunct Associate Professor (with tenure), Department of Biochemistry and Molecular Biology/Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN |
2012-2018 |
Assistant Professor (tenure track), Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN |
2012-2018 |
Adjunct Assistant Professor (tenure track), Department of Biochemistry and Molecular Biology/Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN |
2009-2011 |
Assistant Professor in Molecular Medicine, Lerner College of Medicine at Case Western Reserve University (CWRU), Cleveland, OH |
2006-2011 |
Project Scientist, Department of Molecular Genetics, Cleveland Clinic, Cleveland, OH |
2003-2011 |
Research Associate, Department of Molecular Genetics, Cleveland Clinic, Cleveland, OH |
Honor |
|
2018 |
Keynote Speaker, "Cancer-2018", International Conference on Cancer Research |
2017 |
Faculty Member of the Year, Indiana University School of Medicine, Indianapolis, IN |
2016 |
Trustees’ Teaching Award, Indiana University School of Medicine, Indianapolis, IN |
2015 |
Honorary Keynote Speaker, The Larry Gentry Research Forum, University of Toledo School of Medicine, Toledo, OH |
2015 |
Elwert Award in Medicine, Indiana University School of Medicine, Indianapolis, IN |
2015 |
GlaxoSmithKline's Discovery Fast Track Challenge Nominee, Indiana University, Indianapolis, IN |
2014 |
National Pew Scholar Nominee in Cancer Research, Indiana University, Indianapolis, IN |
2014 |
Young Investigator Travel Award, International Cytokine and Interferon Society Conference |
2013 |
Fellow, Leadership in Academic Medicine Program (LAMP), Indiana University, Indianapolis, IN |
2013 |
F1000 Prime for High Impact Publication, twice |
2012 |
Walther Scholar, Indiana University Walther Oncology Center, Indianapolis, IN |
2009 |
ICS Young Investigator Award, Tri-Society [Society of Leukocyte Biology (SLB) & ICS & ISICR] Conference |
2008 |
Seymour and Vivian Milstein Young Investigator Award, International Society of Interferon & Cytokine Research (ISICR) & ICS Conference |
2007 |
Innovator Award, Cleveland Clinic, Cleveland, OH |
2007 |
Young Investigator Travel Award, International Cytokine Society (ICS) Conference |
2004 |
Young Investigator Travel Award, International Society of Interferon & Cytokine Research (ISICR) Conference |
2004 |
Innovator Award, Cleveland Clinic, Cleveland, OH |
2000 |
Liberato J.A. DiDio Graduate Research Award, University of Toledo School of Medicine, Toledo, OH |
International Professional Activities
Reviewer |
(selected from over 20 journals): Molecular Cellular Biology (MCB), Proc Natl Acad Sci (PNAS), Oncogene, Cancer Research, FASEB J, Scientific Report, Cancer Letter, J Virology, European Journal of Cell Biology (EJCB) |
Member |
Advisory Board, International BIT Annual World Congress of Molecular and Cellular Biology |
Reviewer |
Medical Research Council (MRC), England |
Co-Chair |
2nd International Summit on Integrative Biology |
Session Chair |
International Conference on Retroviruses and Novel Drugs |
Reviewer |
Austrian Science Fund (FWF), Austrian Special Research Program (SFB) |
Member |
Editorial Board, Journal of Clinical Pharmacology and Toxicology (JCPT) |
Reviewer |
The Welcome Trust/DBT India Alliance, Biomedical Fellowship Program |
Member |
Editorial Board, Journal of Pharmacology Research and Toxicology |
Member |
Editorial Board, Clinical Cancer Drugs |
Member |
Editorial Board, The Journal of Gastroenterology & Digestive Systems |
Member |
Editorial Board, SM Journal of Carcinogenesis & Mutagenesis |
Member |
Editorial Board, Journal of Gastroenterology, Hepatology, and Endoscopy |
Member |
Editorial Board, The Scientific Pages of Drug Design and Development |
Session Chair |
International Conference for Biomarkers and Clinical Research
|
Patent Applications
Lu, T and Prabhu, L. Small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and methods of treatment. International Patent Application PCT/US2017/058572, filed on October 26, 2017
Lu, T and Prabhu, L. Small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and methods of treatment. U.S. Provisional Patent Application 62/534,969, filed on July 20, 2017
Lu, T and Prabhu, L. Small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and methods of treatment. U.S. Provisional Patent Application 62/413,341, filed on October 26, 2016
Lu, T and Stark GR. Discovery of the FBXL11 as the negative regulator of NFkB. Filed to the Cleveland Clinic Invention Disclosure in July, 2007, in the process of provisional patent application.
Lu, T, Burdelya, LG, Stark GR and Gudkov AV. Methods of inhibiting apoptosis using latent TGFb. U.S. provisional Patent No. 60/526,667, filed December 2, 2004.
Key Publications
Selected from ~60 publications, Complete list of published work can be found at:
http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/48581694/?sort=date&direction=descending
1. Prabhu, L, Wei, H, Chen, L, Ozlem, D, Amero, A, Sandusky, G, Sun, E, Wang, J, Mo, J, Safa, A, Korc, M, Zhang, Z, and Lu, T*. Innovative AlphaLISA discovers a novel small-molecule inhibitor targeting PRMT5 in pancreatic and colon cancers. Oncotarget 8(25): 39963-39977, 2017. * Corresponding author. - 1) Featured on front cover, Priority Paper, 2) Honorable Mention Award, Cancer Research Day, 3) Honorable Mention, Erica M. Daniel Kepner Award for Scientific Achievement
2. Martin, M, Hua, L, Wang, B, Wei, H, Prabhu, L, Hartley, AV, Jiang, G, Liu, Y, and Lu, T*. Novel serine 176 phosphorylation of YBX1 activates NF-kB in colon cancer. J Biol Chem 292 (8): 3433-3444, 2017. * Corresponding author
3. Wang, B, Wei, H, Prabhu, L, Zhao, W, Martin, M, Hartley, A, and Lu, T*. Role of novel serine 316 phosphorylation of the p65 subunit of NF-kB in differential gene regulation. J Biol Chem 290 (33): 20336-20347, 2015 * Corresponding author - Selected for Donald Bowman Award
4. Lu, T* and Stark, GR*. NF-kB, regulation by methylation. Cancer Res 75 (18): 3692-3695, 2015. * Corresponding authors
5. Wei, H, Wang, B, She, Y, Gopalan, B, Miyagi, M, Stark, GR, and Lu, T*. PRMT5 dimethylates R30 of the p65 subunit to activate NF-kB. Proc Natl Acad Sci USA 110:13516-13521, 2013. *Corresponding Author. -1) Selected for F1000 Prime, 2) Hal Broxymeyer & Victoria Champion Outstanding Publication Award, 3) 2nd Place Award, Cancer Research Day
6. Lu, T*, Yang, M, Huang, D, Ghosh, G, and Stark GR. Role of lysine methyaltion of NF-kB in differential gene regulation. Proc Natl Acad Sci USA 110: 13510-13515, 2013. *Corresponding author - Selected for F1000 Prime
7. Zhang, T, Park, KA, Li, Y, Byun, HS, Jeon, J, Lee, Y, Hong, JH, Kim, JM, Huang, SM, Choi, SW, Kim, SH, Sohn, KC, Ro, H, Lee, JH, Lu, T, Stark, GR, Shen, HM, Liu, ZG, Park, J, and Hur, GM. PHF20 regulates NF-κB signalling by disrupting recruitment of PP2A to p65. Nat Commun 4:2062-2074, 2013.
8. Stark, GR, Wang, Y, and Lu, T. Lysine methylation of promoter-bound transcription factors and relevance to cancer. Cell Res 21(3):375-380, 2011.
9. Lu, T*, Jackson, MW, Wang, B, Yang, M, Chance, M, Miyagi, M, Gudkov, AV, and Stark, GR*. Regulation of NF-kB by NSD1/FBXL11-dependent reversible lysine methyaltion of p65. Proc Natl Acad Sci USA 107: 46-51, 2010 *Corresponding authors
10. Lu, T and Stark, GR. Use of forward genetics to discover novel regulators of NF-kB. Book Chapter in Book "NF-kB". Editors: Michael Karin and Lou Staudt, Cold Spring Harbor Press, p253-264, 2010.
Titles & Appointments
- Associate Professor of Pharmacology & Toxicology
- Adjunct Associate Professor of Biochemistry & Molecular Biology
- Adjunct Associate Professor of Medical & Molecular Genetics
- Showalter Scholar
- Member of "Woman Advisory Council" at IUSM
-
Education
-
Research
-
Professional Organizations
-
Awards